Our health for all commitments
We have 23 forward-looking commitments across the four areas of our responsible business approach.
We aim to tackle some of the biggest global health challenges through addressing unmet medical needs, making our medicines and vaccines more accessible, and strengthening healthcare systems.
Each year we report on our progress against these commitments and here we provide a summary for those that relate to Health for all.
Innovation for unmet medical needs
Adapt the open innovation R&D model, currently used for Diseases of the Developing World, to apply to other areas of great unmet medical need and scientific challenge, including infectious disease and Alzheimer’s disease, by 2015.
- We initiated three new clinical research collaborations at our Africa NCD Open Lab and the lab now has 11 active collaborations that aim to improve our understanding of the nature of asthma, cancer, cardiovascular and kidney disease in African patients.
- We were ranked no.1 of the large pharmaceutical companies in the Access to Medicines Foundation’s first AMR Benchmark.
- Our Diseases of the Developing World centre has supported the phase I clinical trials of a new candidate drug for tuberculosis, with phase II studies expected to begin in 2018.
Building products to better meet needs
Continue to build a core range of products and formats to better meet the needs of people across the globe, including those less able to access and afford our products.
- In 2017, we received a positive scientific opinion from the European Medicines Agency for a new four-dose vial presentation of our Synflorix pneumococcal vaccine, designed specifically to address cold chain challenges by reducing the physical space required during delivery and storage.
- We created and distributed a potentially life-saving medicine to prevent umbilical cord infections, chlorhexidine gel, that has already benefited over 19,000 newborns.
Better access to medicines and vaccines
Further embed our flexible pricing strategy and innovative business models for our prescription medicines and vaccines, to increase usage among those less able to access and afford our products.
- Committed to supply our essential vaccines at the lowest price to internationally recognised civil society organisations supporting refugees where governments are unable to assist
- More than 70% of our vaccine doses go to the least developed, low and middle-income countries. Our lowest vaccine prices are offered to organisations such as Gavi, the Vaccine Alliance, which supports countries with a GNI per head of less than $1,580.
- We have supported Gavi pilots of our Cervarix vaccine for human papillomavaris (HPV) in 12 countries since 2012. In 2018, we will be supplying Cervarix for the first universal mass vaccination programme in Zimbabwe, where cervical cancer is one of the leading causes of deaths among women.
Reducing child mortality
Continue to invest in innovative cross-sector partnerships to reduce child mortality.
Progress: Progressing Completed
- Through our partnership with Save the Children we have reached over 2.7 million children in 41 countries with life-saving interventions.
- GSK employees have raised over £3 million to support the Save the Children partnership.
Strengthening healthcare infrastructure
Continue to work with partners to support the development and strengthening of healthcare infrastructure. We anticipate this could improve access to healthcare for 20 million under-served people by 2020 (vs 2012).
- Continued to re-invest 20% of LDC profits in 39 countries, training 65,000 front line health workers since 2009 and reaching 20m people since 2009.
- Expanded health worker training beyond LDCs to other countries in sub-Saharan Africa, including Botswana, Cameroon and Namibia.
- Extended mVaccination pilots with Vodafone to Nigeria and Tanzania. With the support of the integrated SMS reminders, nearly 200,000 vaccine doses were administered to children using the platform.
Access to antiretroviral treatment for HIV
Through ViiV Healthcare, we will continue to research new treatments, increase access to our medicines and care for people living with HIV around the world. We will support UNAIDS to deliver their 90-90-90 ambition by 2020. We will also work with communities to combat stigma and discrimination associated with HIV.
Progress: Progressing well
- ViiV Healthcare received approval for Juluca, our first single-tablet, 2-drug regimen of dolutegravir and rilpivirine for the maintenance of virologically surpressed HIV patients, following positive phase III results. This marks an important milestone in HIV care by providng a new treatment option that could make a significant difference to people living with HIV by reducing the number of antiretrovirals they have to take.
- Our innovative HIV drug, dolutegravir, was made available as a first line treatment for people living with HIV in Brazil and Botswana, and has been added to the Essential Medicines List in Russia.
- In 2017, Positive Action awarded over 120 new grants across our four main global programmes for men who have sex with men and transgender people, girls and women, adolescents and children.
Build on our 30 year commitment to contribute to the fight against malaria through continued R&D investment and partnerships on the ground.
- We are in late stage development of tafenoquine, a single-dose treatment for P. vivax malaria, which is common in South Asia, the Horn of Africa and Latin America. If approved, tafenoquine will be the first new treatment for P. vivax malaria in over 60 years and has the potential to become an important tool in malaria elimination efforts.
- Through our partnership with Comic Relief we are supporting 20 projects across four African countries and the Greater Mekong sub-region of South East Asia. Across the projects in Tanzania, Ghana and Mozambique that launched in 2017, we have reached over 700,000 people.
Eliminating and controlling tropical diseases
Help to eliminate and control ten neglected tropical diseases that affect 1.4 billion people, by 2020 – including the elimination of lymphatic filariasis, through our continued investment in R&D, ongoing product donations and our contribution to the London Declaration on Neglected Tropical Diseases.
Progress: Progressing well
- Since 1999, donated nearly eight billion tablets of albendazole to eliminate lymphatic filariasis and control intestinal worms.
- Two of our candidate molecules for the treatment of visceral leishmaniasis, discovered in collaboration with Dundee University, are progressing towards clinical studies.
Continue to support the WHO objective of eradicating polio by 2018 by providing vaccines to UNICEF until this is achieved.
Progress: Progressing well
- Delivered more than 300 million doses of oral polio vaccine to UNICEF in 2017, and since 1988, we have contributed over 17 billion doses.
Our responsible business commitments
Our behaviour commitments
We aim to ensure our employees and the third parties we work with act according to our values – patient focus, integrity, respect for people and transparency.
Our people commitments
We aim to create a safe and inclusive workplace where everyone at GSK can feel able and inspired to realise their potential and help us meet global health challenges.